STRATA Skin Sciences Stock Forecast, Price & News

+0.00 (+0.29 %)
(As of 07/27/2021 04:25 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume109 shs
Average Volume72,113 shs
Market Capitalization$50.70 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive SSKN News and Ratings via Email

Sign-up to receive the latest news and ratings for STRATA Skin Sciences and its competitors with MarketBeat's FREE daily newsletter.

STRATA Skin Sciences logo

About STRATA Skin Sciences

STRATA Skin Sciences, Inc., a medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America. The company operates in two segments, Dermatology Recurring Procedures and Dermatology Procedures Equipment. Its products include XTRAC excimer laser and VTRAC lamp systems that are used for the treatment of psoriasis, vitiligo, atopic dermatitis, eczema, and other skin disorders. The company distributes its products internationally through distributors, and domestically directly to physicians. The company was formerly known as MELA Sciences, Inc and changed its name to STRATA Skin Sciences, Inc. in January 2016. STRATA Skin Sciences, Inc. was incorporated in 1989 and is based in Horsham, Pennsylvania.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.99 out of 5 stars

Medical Sector

635th out of 2,218 stocks

Surgical & Medical Instruments Industry

62nd out of 185 stocks

Analyst Opinion: 3.5Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

STRATA Skin Sciences (NASDAQ:SSKN) Frequently Asked Questions

Is STRATA Skin Sciences a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for STRATA Skin Sciences in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" STRATA Skin Sciences stock.
View analyst ratings for STRATA Skin Sciences
or view top-rated stocks.

What stocks does MarketBeat like better than STRATA Skin Sciences?

Wall Street analysts have given STRATA Skin Sciences a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but STRATA Skin Sciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is STRATA Skin Sciences' next earnings date?

STRATA Skin Sciences is scheduled to release its next quarterly earnings announcement on Tuesday, August 10th 2021.
View our earnings forecast for STRATA Skin Sciences

How were STRATA Skin Sciences' earnings last quarter?

STRATA Skin Sciences, Inc. (NASDAQ:SSKN) released its earnings results on Wednesday, May, 12th. The medical device company reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.04) by $0.03. The medical device company had revenue of $5.83 million for the quarter, compared to the consensus estimate of $6.73 million. STRATA Skin Sciences had a negative net margin of 26.12% and a negative trailing twelve-month return on equity of 22.56%.
View STRATA Skin Sciences' earnings history

How has STRATA Skin Sciences' stock been impacted by Coronavirus?

STRATA Skin Sciences' stock was trading at $1.42 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, SSKN stock has increased by 5.6% and is now trading at $1.50.
View which stocks have been most impacted by COVID-19

When did STRATA Skin Sciences' stock split? How did STRATA Skin Sciences' stock split work?

STRATA Skin Sciences's stock reverse split on Thursday, July 10th 2014. The 1-10 reverse split was announced on Thursday, July 3rd 2014. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, July 9th 2014. An investor that had 100 shares of STRATA Skin Sciences stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for SSKN?

3 analysts have issued 1 year target prices for STRATA Skin Sciences' shares. Their forecasts range from $3.00 to $6.00. On average, they anticipate STRATA Skin Sciences' stock price to reach $4.25 in the next twelve months. This suggests a possible upside of 183.3% from the stock's current price.
View analysts' price targets for STRATA Skin Sciences
or view top-rated stocks among Wall Street analysts.

Who are STRATA Skin Sciences' key executives?

STRATA Skin Sciences' management team includes the following people:
  • Mr. Matthew C. Hill, VP & CFO (Age 52, Pay $310.64k)
  • Mr. Robert J. Moccia, Pres, CEO & Director (Age 62)
  • Mr. Jay Sturm, Gen. Counsel & Corp. Sec. (Age 65)
  • Keith Simeone, VP of Sales
  • Dr. Darrell S. Rigel, Chief Medical Advisor (Age 70)
  • Mr. Shmuel Gov, Exec. VP & GM
  • Mr. Nikolai Kabelev, VP of R&D (Age 45)
  • Mr. Michael R. Stewart, Independent Consultant (Age 64)

Who are some of STRATA Skin Sciences' key competitors?

What other stocks do shareholders of STRATA Skin Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other STRATA Skin Sciences investors own include Trevena (TRVN), Amarin (AMRN), Biocept (BIOC), Kopin (KOPN), OPKO Health (OPK), Plug Power (PLUG), AbbVie (ABBV), SCYNEXIS (SCYX), Tonix Pharmaceuticals (TNXP) and Agile Therapeutics (AGRX).

What is STRATA Skin Sciences' stock symbol?

STRATA Skin Sciences trades on the NASDAQ under the ticker symbol "SSKN."

How do I buy shares of STRATA Skin Sciences?

Shares of SSKN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is STRATA Skin Sciences' stock price today?

One share of SSKN stock can currently be purchased for approximately $1.50.

How much money does STRATA Skin Sciences make?

STRATA Skin Sciences has a market capitalization of $50.70 million and generates $23.09 million in revenue each year. The medical device company earns $-4,410,000.00 in net income (profit) each year or ($0.13) on an earnings per share basis.

How many employees does STRATA Skin Sciences have?

STRATA Skin Sciences employs 109 workers across the globe.

What is STRATA Skin Sciences' official website?

The official website for STRATA Skin Sciences is

Where are STRATA Skin Sciences' headquarters?

STRATA Skin Sciences is headquartered at 5 WALNUT GROVE DRIVE SUITE 140, HORSHAM PA, 19044.

How can I contact STRATA Skin Sciences?

STRATA Skin Sciences' mailing address is 5 WALNUT GROVE DRIVE SUITE 140, HORSHAM PA, 19044. The medical device company can be reached via phone at (215) 619-3200 or via email at [email protected]

This page was last updated on 7/27/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.